

## Therapeutic Tolerance: From Bench to Bedside and Back Again

29<sup>th</sup> June – 3<sup>rd</sup> July 2026

The Catalyst  
3 Science Square  
Newcastle Helix  
Newcastle  
NE4 5TG

[Google Maps Link](#)

### Programme

#### Monday 29th June

11:00	Registration	<i>A light lunch will be included</i>
	Professor John Isaacs	Welcome introduction and housekeeping
<i>Session 1 – Immune regulation</i> <i>Chaired by: John Isaacs</i>		
	Dan Mueller (Minnesota)	Anergy as a mechanism of tolerance – therapeutic implications
	Peter Nigrovic (Boston)	Different Treg flavours
	Tak Mak (Toronto)	Cholinergic regulation of tolerance
	TBC	
	Discussion	
<i>Session 2 – Depleting B-cells</i> <i>Chaired by:</i>		
	Georg Schett (Erlangen)	B-cell depletion - the story so far
	Ricardo Grieshaber (Erlangen)	Immune cell engagers - from mechanism to efficacy
	Maria Leandro (London)	Monoclonal antibodies for depleting B-cells
	Uli Scherer (Leiden)	Which B-cells to deplete?
	Discussion	
Coffee break (poster/exhibitor viewing)		
<i>Session 3 – Oral presentations (1)</i> Short oral presentations selected from submitted abstracts <i>Chaired by:</i>		
<i>Session 4– Poster Session (1)</i>		
17:10	Poster Viewing and Pizza	
19:00 CLOSE		

#### Tuesday 30th June

8:00	Tea/coffee on arrival	
	Keynote speaker: Mark Anderson (San Francisco)	Non-antigen-specific approaches to therapeutic tolerance
<i>Session 5 – Immune checkpoints</i>		
<i>Chaired by:</i>		
	Simon Davis (Oxford)	Manipulating immune checkpoints for tolerance
	TBC	
	Deepak Rao (Boston)	Immune checkpoint inhibitor control of T cell autoimmunity
	Arthur Pratt (Newcastle)	Dissecting checkpoint inhibitor arthritis
	Ethan Shevach (Bethesda)	MHC class I-based checkpoint inhibitors
	Discussion	
Coffee Break		
<i>Session 6– Clinical trials (1) – What have we learned from...?</i>		
<i>Chaired by:</i>		
	Colin Dayan (Birmingham)	Trials in type 1 diabetes?
	Roland Martin (Zurich)	Trials in multiple sclerosis?
	Ludwig Sollid (Oslo)	Trials in coeliac disease?
	Ranjeny Thomas (Brisbane)	Trials in rheumatoid arthritis?
	David Wraith (Birmingham)	Tolerance-inducing peptides (moved from Thu Session 19)
	Discussion	
Lunch		
<i>Session 7– Biomarkers (1)</i>		
<i>Chaired by:</i>		
	Vivi Malmstrom (Stockholm)	Enumerating and characterising T-cells
	Bill Robinson (San Francisco)	What can we learn from lymphocyte receptor sequencing?
	Tim Tree (London)	Measuring autoreactivity
	Rene Toes (Leiden)	V-region Glycosylation
	Discussion	
Coffee Break		
<i>Session 8 – Oral presentations (2) Short oral presentations selected from submitted abstracts</i>		
<i>Chaired by:</i>		
<i>Session 9 – Microbiome</i>		
<i>Chaired by:</i>		
	Simon Milling (Glasgow)	Mucosal immunology and tolerance
	Mahesh Desai (Luxembourg)	Manipulating the microbiome for therapeutic purposes
	Fiona Powrie (Oxford)	Inflammatory bowel disease, autoimmunity and the microbiome
	Discussion	
<i>The Great Debate (1) - B-cell depletion - the holy grail of therapeutic tolerance</i>		
<i>Chaired by: John Isaacs</i>		
	For the motion	Georg Schett (Erlangen)
	Against the motion	Iain McInnes (Glasgow)
	Discussion	
	Vote	
17:45 CLOSE – Leave for BBQ at ABOVE Vermont		

**Wednesday 1st July**

8:00	Tea/coffee on arrival	
	Keynote speaker: Luke O'Neill (Dublin)	Manipulating immunometabolism as a route to therapeutic tolerance
<i>Session 10 – Industry showcase (1) (short talks; 10+2)</i>		
<i>Chaired by:</i>		
	Paul Peloso (Cour)	
	Cristina de Min (Topas)	Targeting liver sinusoidal endothelium
	Dan Baker (Cue Bio)	Novel approaches to Treg induction
Coffee Break		
<i>Session 11– Disease prevention</i>		
<i>Chaired by:</i>		
	Kevin Deane (Denver)	Immunology of the at-risk state
	Lars Klareskog (Stockholm)	Where does autoimmunity start?
	Andy Cope (London)	Immune checkpoints and disease prevention
	Amy Anderson (Newcastle)	What can we learn from studying flare?
	Discussion	
<i>Session 12– Tolerance Collaborations</i>		
<i>Chaired by:</i>		
	Ranjeny Thomas (Brisbane)	Australia RESET-RA
	Adam Croft (Birmingham)	UK RESET
	Iain McInnes (Glasgow)	FOREUM
	Discussion	
Lunch		
<i>Session 13 – Transplantation</i>		
<i>Chaired by:</i>		
	Fadi Issa (Oxford)	Expanded Tregs in human transplantation
	Anna Weiljer (Vienna)	Chimerism in transplantation
	Angus Thomson (Pittsburgh)	Negative vaccination for transplantation tolerance
	Aurelie Moreau (Nantes)	Immunometabolism in kidney transplantation
	Discussion	
Coffee Break		
<i>Session 14 – Permissive environments for tolerance</i>		
<i>Chaired by:</i>		
	Chris Buckley (Oxford)	Fibroblast heterogeneity-implications for therapeutic tolerance
	Mariola Kurowska-Stolarska (Glasgow)	Tissue myeloid immune checkpoints: role in maintaining and re-establishing homeostasis
	Jeffrey Hubbell (New York)	Liver-targeted tolerogens
	Kingston Mills (Dublin)	IL17 - friend or foe for tolerance?
	Discussion	
16:50 Poster Session (2)		
18:00 CLOSE- Leave for Wylam Brewery for Workshop Dinner		

## Thursday 2nd July

8:00	Tea/coffee on arrival	
	Keynote speaker: Sophie Hambleton (Newcastle)	Lessons in tolerance from inherited immune deficiencies
<i>Session 15 – Cellular therapies</i>		
<i>Chaired by:</i>		
	Maria Grazia Roncarolo (San Francisco)	TR1 cells as therapeutics
	John Isaacs (Newcastle)	AuToDeCRA-2 trial
	Eva Martinez-Caceres (Barcelona)	ToIDC in multiple sclerosis
	Petra Reinke (Berlin)	Next generation Tregs
	Alberto Sanchez Fueyo (London)	CAR T-regs in transplantation
	Discussion	
Coffee Break		
<i>Session 16 – Immunometabolism</i>		
<i>Chaired by:</i>		
	Claudia Mauri (London)	Metabolic control of Bregs
	TBC	TBC
	Ursula Fearon (Dublin)	Immunometabolism in rheumatoid arthritis
	Discussion	
<i>Session 17 – Industry showcase (2)</i>		
<i>Chaired by:</i>		
	Marc Martinez-Llordella (Quell)	CD19 CAR-Tregs in rheumatic disease
	Carole Guillonnet (Aboleris)	Targeting CD45RC for tolerance
	Nova Pishesha (Cerberus)	Targeting MHCII for tolerance
	TBC	
Lunch		
<i>Session 18– Big Data</i>		
<i>Chaired by:</i>		
	Stefano Alivernini (Rome)	Tissue myeloid-based tools in experimental rheumatology
	Lisa van Baarsen (Amsterdam)	Lymph nodes and autoimmunity
	Jaume Bacardit (Newcastle)	Making sense of the data using AI
	Mark Coles (Oxford)	Modelling tolerance/systems immunology
	Discussion	
Coffee Break		
<i>Session 19 – Tregs (2)</i>		
<i>Chaired by:</i>		
	Bart Roep (Leiden)	How do Tregs work anyway?
	TBC	TBC
	Kevan Herold (New Haven)	What have we learned about anti-CD3 as a tolerogen?
	Shimon Sakaguchi (Osaka)	Soluble CTLA4 and immune homeostasis
	Discussion	
<i>The Great Debate (2) - TBC</i>		
17:50	Close Leave for Biscuit Factory for workshop dinner	

## Friday 3rd July

8:00	Tea/coffee on arrival	
	Keynote speaker: Shimon Sakaguchi (Osaka)	Regulatory T-cells – a retrospective and commentary on progress
<i>Session 20 – Transplantation (2)</i>		
<i>Chaired by:</i>		
	Alexandra Kreins (London)	What can we learn about tolerance from human thymus transplantation?
	Andrew Fisher (Newcastle)	Reducing transplant immunogenicity
	Jaap van Laar (Utrecht)	Autologous stem cell transplantation and tolerance
	Alessandro Alessandrini (Boston)	B-cells as biomarkers in transplantation
	Discussion	
Coffee Break		
<i>Session 21 – TBC</i>		
<i>Chaired by:</i>		
12:12	Closing remarks	